Biotech/ Pharma Stock Trading Alert; BioSante Pharmaceuticals Inc up on News
Point Roberts, WA. –February 14, 2011 (Investorideas.com Energy stocks Newswire) -
www.InvestorIdeas.com and its leading Biotech investor portals, announces a technical stock
trading alert for BioSante Pharmaceuticals Inc (NASDAQ:BPAX). The stock is trading at $2.41,
up 0.10 (4.33%), trading as high as $2.53 in morning trading.
Biotech/Pharma Stock News; BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program
Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. To Present LibiGel Safety Study Update at BIO CEO & Investor Conferenc
LINCOLNSHIRE, Ill. - February 14, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14-15, 2011 at the Waldorf-Astoria in New York.
BioSante's (NASDAQ: BPAX) Senior V.P. Michael Snabes, MD, PhD, to Discuss Data From LibiGel® Safety Study
LINCOLNSHIRE, Ill. - February 10, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports it will provide a LibiGel safety study update, in addition to supporting two clinical symposia, at the Annual Meeting of The International Society for the Study of Women's Sexual Health Meeting (ISSWSH).
Q&A with Josh Levine of MicroCap Investor; Winning Strategy for Stocks in Biotech, Cleantech, and Emerging Technologies
Key Highlight: BioSante Pharmaceuticals is Only Company in World In Phase III Clinical Development for Treatment of Female Sexua
Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. To Provide Update on LibiGel Safety Study at International Society for
Biotech/Pharma Stocks News; UV Flu Technologies to Become an Official Equipment Supplier to Hockey Canada
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Completes Acquisition of RxAir Industries
Biotech/Pharma Stock News; BioSante (NASDAQ: BPAX) Announces FDA Orphan Drug Designation for its Melanoma Cancer Vaccine
LINCOLNSHIRE, Ill. - January 25, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer. Orphan drug designation, as granted by the U.S.